TOP BIOPHARMACEUTICAL COMPANIES BY REVENUES IN 2021
Revenues in billions
Also read: Italy healthcare system
1. JOHNSON AND JOHNSON
Q1 RESULTS
Johnson and Johnson reported sales of $ 22.32 billion in the first quarter of 2021. The company reported growth of 7.9%, operational growth of 5.5%, and 6.0% adjusted operational growth.
Consumer health products contributed $ 3.5 billion, pharmaceuticals contributed $ 12.2 billion, and medical devices grew by $ 6.6 billion.
Stelara sales were $ 2.148 billion, Prezista / Prezcobix / Rezolsta / Symtuza contributed to $ 546 million, Invega Sustenna / Xeplion / Invega Trinza / Trevicta revenues contributed to $ 965 million, Darzalex revenues were $ 1.365 billion, Imbruvica sales were $ 1.125 billion, and Opsumit sales were $ 450 million.
Also read: Denmark Healthcare System
Q2 RESULTS
The company has reported an increase of 27.1% in sales compared to 2020; the company reported revenues of $23.3 billion in the second quarter of 2021. The pharmaceutical sector contributed $12.6 billion, consumer health products added $3.7 billion, and medical devices contributed $6.97 billion.
Stelara sales were $2.27 billion, Tremfya sales were $0.48 billion, Darzalex sales were $1.43 billion, and Opsumit sales were $0.46 billion.
Also read: Spinal muscular atropy news
Q3 RESULTS
Johnson and Johnson reported an increase of 10.7% in revenue; the company reported sales of $23.3 billion. The pharmaceutical segment reported sales of $13 billion, an increase of 13.8%. Consumer health sales increased by 5.3% and medical devices by 8.0%.
Also read: Denmark healthcare system
Q4 REVENUES
Johnson and Johnson reported full-year results; the fourth-quarter revenues were $24.8 billion.
The total revenues of Johnson and Johnson in 2021 are $93.78 billion. The pharmaceutical segment revenues were $50.08 billion, medical devices revenues were $27.06 billion, and consumer health revenues were $14.64 billion.
The company has reported an increase in pharmaceutical revenues by 13.6%, primarily driven by the sales of Darzalex (daratumumab), Stelara (ustekinumab), Imbruvica, and Remicade.
Top selling brands of Johnson and Johnson
2. PFIZER
Q1 RESULTS
Pfizer reported phenomenal results in the Q1 of 2021, primarily because of its COVID19 vaccine. The company reported sales of $14.6 billion; the operational incomes increased by 8%.
COVID19 vaccine revenues were $3.5 billion.
Ibrance revenues were $12 billion, a slight decrease of 1%. Eliquis revenues were $1.6 billion, Xeljan reported sales of $0.45 billion.
FULL YEAR RESULTS
Pfizer reported full year revenues of $81.29 billion.
Best selling products
3. ROCHE
Q1 RESULTS
Roche reported revenues of $ 16.27 billion. The group revenues increased by 3%.
Pharmaceutical revenues decreased by 9%, primarily because of the impact of pandemic and biosimilars.
The group has reported a reduction in sales by CHF 1.6 billion because of the biosimilars of MabThera/Rituxan, Avastin, and Herceptin.
Ocrevus reported sales of CHF 1.2 billion, Perjeta sales were CHF 988 million, Tecentriq sales were CHF 775 million, and Hemlibra sales were CHF 661 million.
Also read: Top 10 pharmaceutical companies by revenues in 2020
H1 RESULTS
The company reported sales of CHF 30.7 billion in the first six months of 2021. The pharmaceuticals revenue dropped by 3%, and diagnostics sales were increased by 51% at CER.
The drop in sales of pharmaceuticals is primarily because of the biosimilars of Avastin and Rituxan; however, the innovative products have driven the sales. Hemlibra revenues increased by 45%, Tecentriq by 29%, and Ocrevus by 23%.
Q3 RESULTS
Roche reported sales of CHF 46.68 billion in the first three months of 2021. The company reported a growth of 8% at a constant exchange rate and 6% in Swiss Francs.
The pharmaceutical sales decreased by 3%; however, the diagnostic sales increased by 38%.
FULL YEAR RESULTS
Roche reported $68.07 billion (CHF 62.80 billion) in 2021. The company has reported an increase of 9% in revenues, pharmaceutical division sales increased by 3%.
Best selling products of Roche
4. ABBVIE
Q1 RESULTS
AbbVie reported an increase in sales by 51%, reported sales of $ 13 billion.
Humira sales were increased by 3.5%; global revenues were $4.87 billion. Skyrizi revenues were %574 million, and Rinvoq sales were $303 million.
Global revenues of Imbruvica were $1.27 billion, and Venclexta was $405 million.
Also read: Italy healthcare system
Q4 RESULTS
AbbVie reported revenues of $14.89 billion in Q4 of 2021. In Q4, Humira revenues were $5.33 billion, Imbruvica revenues were $1.39 billion, Skyrizi revenues were $895 million.
FULL-YEAR SALES:
AbbVie reported total sales of $56.20 billion in 2021.
Best selling products of AbbVie are
5. NOVARTIS
Q1 RESULTS
Novartis reported a decline in sales by 2% because of the COVID-19 related forward purchasing. Sandoz sales declined by 13%. The company announced that COVID-19 impacted dermatology, ophthalmology, breast cancer, Sandoz retail, and anti-infectives.
Also read: United States Healthcare System
The core operating income was declined by 8%. Net income was decreased by 7%, mainly because of the low operating income. Core operating income reduced by 8%, and core net income declined by 6%.
Also read: Denmark Healthcare System
Cosentyx sales were increased by 11%, reported sales of $ 1.1 billion. Zolgensma sales increased by 81%, with reported sales of $ 319 million. Entresto sales grew by 34%, reported revenues of $789 million, Promacta sales increased by 13% ($ 463 million). Kymriah sales increased by 55% ($ 151 million).
Q2 RESULTS
Novartis reported an increase in revenues by 9%. The pharmaceuticals BU sales grew by 12%, Oncology BU grew by 7%, and Sandoz sales grew by 5%.
Cosentyx sales were $ 1.2 billion (+21%), Entresto sales were $ 0.89 billion (+ 46%), Zolgensma sales were 0.32 billion, Promacta reported sales of 0.5 billion (+18%).